TransCode Therapeutics, Inc.
RNAZNASDAQHealthcare● Active
$5.09
$-0.51(-9.11%)
Market Cap$4837032
P/E Ratio—
52W High$20.99
52W Low$3.82
TransCode Therapeutics, Inc. (RNAZ) · Balance Sheet
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RNAZ · as of 2026-06-10
Financial statements
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $0.02B | $0.01B | $0.00B | $0.00B | $0.02B |
| Net Receivables | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Inventory | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Assets | $0.02B | $0.01B | $0.00B | $0.01B | $0.02B |
| PP&E Net | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Goodwill | $0.03B | $0.00B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.11B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Assets | $0.16B | $0.01B | $0.01B | $0.01B | $0.02B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Accounts Payable | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Current Liabilities | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | $0.15B | $0.01B | $0.00B | $0.00B | $0.00B |
| Stockholders Equity | |||||
| Retained Earnings | ($0.10B) | ($0.06B) | ($0.05B) | ($0.03B) | ($0.01B) |
| Total Stockholders Equity | $0.01B | ($0.00B) | $0.00B | $0.00B | $0.02B |
| Total Liab & Equity(computed) | $0.16B | $0.01B | $0.01B | $0.01B | $0.02B |
| Debt Summary | |||||
| Total Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Debt | ($0.02B) | ($0.01B) | ($0.00B) | ($0.00B) | ($0.02B) |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more TransCode Therapeutics, Inc. data
About TransCode Therapeutics, Inc. (RNAZ) Balance Sheet
TransCode Therapeutics, Inc. (RNAZ) balance sheet shows total assets of $0.16B with cash of $0.02B. Total liabilities are $0.15B, total debt $0.00B, and stockholders equity $0.01B.
Frequently asked questions
RNAZ · 4 questionsTransCode Therapeutics, Inc. has total debt of $0.00B with net debt of ($0.02B).
RNAZ total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10